Reinvestigation of the Synthesis of Ketanserin (5) and its Hydrochloride Salt (5.HCl) via 3-(2-Chloroethyl)-2,4-(1H, 3H)-quinazolinedione (2) or Dihydro-5H-oxazole(2,3-b) quinazolin-5-one (1)

被引:10
|
作者
Fakhraian, Hossein [1 ]
Heydary, Mehdi [1 ]
机构
[1] Imam Hossein Univ, Dept Chem, Tehran, Iran
关键词
VALENT TITANIUM REAGENT; PHARMACOKINETICS; AID;
D O I
10.1002/jhet.1897
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The synthesis of ketanserin (5) and its hydrochloride salt (5.HCl) using respectively equimolar amounts of 3-(2-chloroethyl)-2,4-(1H,3H)-quinazolinedione (2) with 4-(parafluorobenzoyl)piperidine (3) and dihydro-5H-oxazole(2,3-b)quinazolin-5-one (1) with hydrochloride salt of 4-(parafluorobenzoyl)piperidine (3.HCl) is reinvestigated. The one-pot reaction of ethyl-2-aminobenzoate with ethyl chloroformate and ethanol amine has afforded 3-(2-chloroethyl)-2,4-(1H,3H)-quinazolinedione (2) (86%) that was then refluxed with 4-(parafluorobenzoyl)piperidine (3) in ethyl methyl ketone in the presence of sodium carbonate to obtain free base of ketanserin (87%). In another attempt, a very pure hydrochloride salt of ketanserin (5.HCl) was synthesized using equimolar amounts of dihydro-5H-oxazole(2,3-b)quinazolin-5-one (1) and hydrochloride salt of 4-(parafluorobenzoyl)piperidine (3.HCl) by a solvent-less fusion method. Thus, under optimized conditions, 180 degrees C and a reaction time of 30min, the powder mixture was transformed into glassy crystals that were initially readily soluble in chloroform but were transformed afterwards over time (2h) to white precipitates (5.HCl) suspended in chloroform with a yield of 72%.
引用
收藏
页码:151 / 156
页数:6
相关论文
共 21 条
  • [1] Synthesis of new pyrimidine-containing compounds: 5-(2-(alkylamino)-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-6-hydroxypyrimidine-2,4(1H,3H)-dione derivatives
    Kochia, Khudaidad
    Bayat, Mohammad
    Nasri, Shima
    Mohammadi, Aref
    MOLECULAR DIVERSITY, 2020, 24 (04) : 1015 - 1024
  • [2] VENTRICULOLUMBAR PERFUSION OF 3-[(4-AMINO-2-METHYL-5-PYRIMIDINYL)METHYL]-1-(2-CHLOROETHYL)-1-NITROSOUREA HYDROCHLORIDE
    KOCHI, M
    KURATSU, J
    MIHARA, Y
    TAKAKI, S
    SETO, H
    UEMURA, S
    USHIO, Y
    SHAPIRO, WR
    LEVIN, VA
    NEUROSURGERY, 1993, 33 (05) : 817 - 823
  • [3] Deuteration and fluorination of 1,3-bis(2-phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione to improve its pharmacokinetic properties
    Xia, Guoyao
    Benmohamed, Radhia
    Morimoto, Richard I.
    Kirsch, Donald R.
    Silverman, Richard B.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (21) : 5098 - 5101
  • [4] Determination of 5-n-Butyl-4-{4-[2-(1H-tetrazole-5-yl)1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one,a new Angiotensin type 1 receptor antagonist in rat plasma by LC-ESI-MS: Application to pharmacokinetic studies
    Yan, Bei
    Wang, Guang-ji
    Sun, Jian-Guo
    Sun, Fen-zhi
    Li, Xiao-Yu
    Wu, Xiao-ming
    Xu, Jin-yi
    Zheng, Yuan-ting
    Lv, Hua
    CHROMATOGRAPHIA, 2007, 66 (1-2) : 55 - 61
  • [5] Determination of 5-n-Butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one, a New Angiotensin Type 1 Receptor Antagonist in Rat Plasma by LC-ESI-MS: Application to Pharmacokinetic Studies
    Bei Yan
    Guang-ji Wang
    Jian-guo Sun
    Fen-zhi Sun
    Xiao-yu Li
    Xiao-ming Wu
    Jin-yi Xu
    Yuan-ting Zheng
    Hua Lv
    Chromatographia, 2007, 66 : 55 - 61
  • [6] Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators
    Sharma, Swagat
    Kozek, Krystian A.
    Abney, Kristopher K.
    Kumar, Sushil
    Gautam, Nagsen
    Alnouti, Yazen
    Weaver, C. David
    Hopkins, Corey R.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (06) : 791 - 796
  • [7] Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors
    Han, Sun-Young
    Choi, Jie Won
    Yang, Jeon
    Chae, Chong Hack
    Lee, Jongkook
    Jung, Heejung
    Lee, Kwangho
    Ha, Jae Du
    Kim, Hyoung Rae
    Cho, Sung Yun
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (08) : 2837 - 2842
  • [8] Efficacy and pharmacokinetics evaluation of 4-(2-chloro-4-fluorobenzyl)-3-(2-thienyl)-1,2,4-oxadiazol-5(4H)-one (GM-90432) as an anti-seizure agent
    Hwang, Kyu-Seok
    Kan, Hyemin
    Kim, Seong Soon
    Chae, Jin Sil
    Yang, Jung Yoon
    Shin, Dae-Seop
    Ahn, Se Hwan
    Ahn, Jin Hee
    Cho, Jin-Hwa
    Jang, Il-Sung
    Shin, Junnyeong
    Joo, Jaeyoung
    Kim, Cheol-Hee
    Bae, Myung Ae
    NEUROCHEMISTRY INTERNATIONAL, 2020, 141
  • [9] Determination of a novel TAZ modulator, 2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2′-(1H-tetrazole-5-yl)-biphenyl-4-ylmethyl]-3H imidazo[4,5-b]pyridine] (TM-25659) in rat plasma by liquid chromatography-tandem mass spectrometry
    Choi, Sung Heum
    Lee, Kyeong-Ryoon
    Woo, Jae-Chun
    Kim, Nak Jeong
    Moon, Dong Cheul
    Hwang, Eun Sook
    Ahn, Sung-Hoon
    Bae, Myung Ae
    Kim, Min-Sun
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2012, 63 : 47 - 52
  • [10] Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: Discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
    Hughes, Robert O.
    Walker, John K.
    Rogier, D. Joseph
    Heasley, Steve E.
    Blevis-Bal, Rhadika M.
    Benson, Alan G.
    Jacobsen, E. Jon
    Cubbage, Jerry W.
    Fobian, Yvette M.
    Owen, Dafydd R.
    Freskos, John N.
    Molyneaux, John M.
    Brown, David L.
    Acker, Brad A.
    Maddux, Todd M.
    Tollefson, Mike B.
    Moon, Joseph B.
    Mischke, Brent V.
    Rumsey, Jeanne M.
    Zheng, Yi
    MacInnes, Alan
    Bond, Brian R.
    Yu, Ying
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (17) : 5209 - 5213